Volastra
Gerard Evan studied Biochemistry at Oxford, did his Ph.D. at the MRC Laboratory of Molecular Biology in Cambridge and was a post-doc in Mike Bishop’s laboratory at the University of California San Francisco (UCSF). After a brief return to Cambridge as a research fellow at Downing College he moved to the Imperial Cancer Research Fund Laboratories in London in 1988. He was elected to the Royal Society’s Napier Research Professorship in 1996. In 1999, he was appointed Gerson and Barbara Bass Bakar Distinguished Professor of Cancer Research at UCSF, subsequently returning in 2009 to Cambridge as become the Sir William Dunn Professor and Head of Biochemistry. Gerard was elected to EMBO in 1996, the UK Academy of Medical Sciences in 1999, the Royal Society in 2004, the European Academy of Sciences in 2006, the European Academy of Cancer Sciences in 2013 and the Academy of the American Association for Cancer Research in 2019.
This person is not in the org chart
This person is not in any offices
Volastra
1 followers
Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics.